Literature DB >> 31243647

Neurocognitive outcomes in long-term survivors of Wilms tumor: a report from the St. Jude Lifetime Cohort.

Ingrid Tonning Olsson1, Tara M Brinkman1,2, Geehong Hyun1, Pia Banerjee1, Daniel A Mulrooney1,3, I-Chan Huang1, Daniel M Green1,3, Deokumar Srivastava4, Leslie L Robison1, Melissa M Hudson1,3, Kevin R Krull5,6.   

Abstract

PURPOSE: To examine prevalence and predictors of neurocognitive outcomes, social attainment, emotional distress, and health-related quality of life (HRQOL) in long-term survivors of pediatric Wilms tumor (WT).
METHODS: One hundred fifty-eight WT survivors (59% female; mean [SD] age 33 [9.1] years; time since diagnosis 29 [9.1] years) and 354 community controls (55.6% female; 35 [10.2] years) completed comprehensive neuropsychological testing and physical examination, including echocardiography/electrocardiography, pulmonary function tests, and endocrine evaluation. Self-report of emotional distress, HRQOL, and social attainment were collected. Impairment was defined in relation to both controls and normative data. Generalized linear models were developed to examine impact of treatment and chronic health conditions on outcomes.
RESULTS: WT survivors performed poorer than norms and controls in 6 of 16 cognitive variables and 1 of 8 HRQOL variables, with scores ranging from - 0.64 (mathematics) to - 0.21 (verbal fluency) standard deviations below expectations. Compared to controls, WT survivors were less likely to graduate college (odds ratio 2.23, 95% confidence interval 1.46-3.41) and had more moderate to severe neurologic conditions (18.4% vs 8.2%, p < 0.001), which were associated with poor memory (β = - 0.90, p < 0.001), attention (β = - 1.02, p < 0.001), and HRQOL general health (β = - 0.80, p = 0.0015). Treatment variables and cardiopulmonary morbidity (higher in survivors) were not associated with outcomes.
CONCLUSIONS: Survivors of WT demonstrate impairment in neurocognitive function and have lower social attainment during adulthood, with poorer neurocognitive function associated with neurologic morbidity. IMPLICATIONS FOR CANCER SURVIVORS: Survivors of WT should be offered neurocognitive evaluations and rehabilitation. Neurologic conditions should be routinely assessed, and appropriate support offered to reduce risk for functional limitations.

Entities:  

Keywords:  Emotional distress; Health-related quality of life; Neurocognition; Pediatric Wilms tumor; Social attainment

Mesh:

Year:  2019        PMID: 31243647      PMCID: PMC6679797          DOI: 10.1007/s11764-019-00776-8

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  48 in total

Review 1.  SF-36 health survey update.

Authors:  J E Ware
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-15       Impact factor: 3.468

2.  Adult psychosocial outcomes in long-term survivors of acute lymphoblastic leukaemia and Wilms' tumour: a controlled study.

Authors:  E Mackie; J Hill; H Kondryn; R McNally
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

3.  Subtle white matter volume differences in children treated for medulloblastoma with conventional or reduced dose craniospinal irradiation.

Authors:  W E Reddick; J M Russell; J O Glass; X Xiong; R K Mulhern; J W Langston; T E Merchant; L E Kun; A Gajjar
Journal:  Magn Reson Imaging       Date:  2000-09       Impact factor: 2.546

4.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

Review 5.  Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed.

Authors:  V L Stott; M A Hurrell; T J Anderson
Journal:  Intern Med J       Date:  2005-02       Impact factor: 2.048

6.  Diabetic peripheral neuropathy and depressive symptoms: the association revisited.

Authors:  Loretta Vileikyte; Howard Leventhal; Jeffrey S Gonzalez; Mark Peyrot; Richard R Rubin; Jan S Ulbrecht; Adam Garrow; Christine Waterman; Peter R Cavanagh; Andrew J M Boulton
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

7.  Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity.

Authors:  Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman
Journal:  Pediatr Blood Cancer       Date:  2005-09       Impact factor: 3.167

8.  Health-related quality of life in survivors of Wilms' tumor and advanced neuroblastoma: aA cross-sectional study.

Authors:  R D Barr; D Chalmers; S De Pauw; W Furlong; S Weitzman; D Feeny
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

9.  Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia.

Authors:  R K Shin; J W Stern; A J Janss; J V Hunter; G T Liu
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

10.  Long-term survivors of leukemia treated in infancy: factors associated with neuropsychologic status.

Authors:  R K Mulhern; E Kovnar; J Langston; M Carter; D Fairclough; L Leigh; L E Kun
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

View more
  2 in total

Review 1.  Aging in Adult Survivors of Childhood Cancer: Implications for Future Care.

Authors:  Ilse Schuitema; Tyler Alexander; Melissa M Hudson; Kevin R Krull; Kim Edelstein
Journal:  J Clin Oncol       Date:  2021-04-22       Impact factor: 50.717

2.  Physiologic Frailty and Neurocognitive Decline Among Young-Adult Childhood Cancer Survivors: A Prospective Study From the St Jude Lifetime Cohort.

Authors:  AnnaLynn M Williams; Kevin R Krull; Carrie R Howell; Pia Banerjee; Tara M Brinkman; Sue C Kaste; Robyn E Partin; Deokumar Srivastava; Yutaka Yasui; Gregory T Armstrong; Leslie L Robison; Melissa M Hudson; Kirsten K Ness
Journal:  J Clin Oncol       Date:  2021-07-20       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.